uniQure N.V. (NASDAQ:QURE) is a biotechnology company developing gene therapies for rare genetic disorders. Its lead pipeline gene therapy is AMT-061 (etranacogene dezaparvovec) for the treatment of Hemophilia-B. In Nov 2022, regulators have approved this drug. Priced at $3.5million per dose, this is currently the world’s most expensive medicine. In this investment case study, we will analyze the company’s financials, competitive landscape, and potential risks and rewards associated with investing in uniQure N.V. https://www.businessinsider.com/fda-approves-worlds-most-expensive-drug-costing-35-million-patient-2022-11 Advertisements Company Overview UniQure N.V. is a biotechnology company based in Amsterdam, Netherlands. The company specializes in the development of gene therapies for rare genetic disorders. Its lead pipeline gene therapy is AMT-061 (etranacogene dezaparvovec) for the treatment of Hemophilia-B. In November 2022, regulators approved this drug, making it the world’s most expensive medicine, priced at $3.5 million per dose. The gene therapy will be manufactured in Lexington, Massachusetts, by uniQure NV, which sold the commercialization rights for Hemgenix to CSL Behring in 2020....